Dr. Weisman Quoted in NY Times Article on Aducanumab

One neurologist, Dr. David Weisman, who said he was not involved with aducanumab’s trials but had worked with other anti-amyloid drugs, wrote that Medicare should require safety monitoring and medical expertise. But because the F.D.A. approved Aduhelm, he wrote, whether to use it “should be left to individual patients, family members and physicians.”